Carasent AB (CARA) AI Stock Analysis

• Market Cap: kr1.89B
• Dividend Yield: N/A
• Average Volume (3M): 175.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.05
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 196
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.20
• Shares Outstanding: 72,324,780
• 10 Day Avg. Volume: 229,351
• 30 Day Avg. Volume: 175,329
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: kr29.00 ▲(10.69% Upside)

Carasent AB's overall score reflects strong technical momentum and a solid financial foundation, but is significantly impacted by profitability and valuation challenges. Improving net income and cash flow are critical for enhancing investor confidence.

Carasent AB Business Overview & Revenue Model

Company Description

Carasent AB (CARA) is a Swedish technology company primarily focused on providing innovative digital solutions for the healthcare sector. The company specializes in the development and implementation of electronic health record (EHR) systems, telemedicine platforms, and data analytics tools aimed at improving patient care and operational efficiency. With a commitment to enhancing healthcare delivery, Carasent operates in various sectors, including hospitals, clinics, and outpatient services, delivering products that facilitate better healthcare management and patient engagement.

How the Company Makes Money

Carasent AB generates revenue through multiple key streams, primarily by offering subscription-based EHR solutions and related healthcare technology services to healthcare providers. The company charges clients recurring fees for access to its software platforms, which are tailored to meet the specific needs of healthcare organizations. Additionally, Carasent earns revenue through professional services, including implementation, training, and ongoing support for its software solutions. Strategic partnerships with healthcare institutions and technology providers also enhance its market reach and contribute to its earnings, as these collaborations often lead to joint offerings and expanded customer bases.

Carasent AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	313.11M	―	275.26M	243.98M	195.26M	137.13M
Gross Profit	264.75M	―	232.71M	197.77M	161.42M	112.90M
EBITDA	23.77M	―	17.52M	2.91M	58.81M	17.91M
Net Income	-34.76M	―	-42.26M	-46.45M	31.17M	-148.00K
Balance Sheet
Total Assets	1.06B	―	1.07B	1.09B	1.37B	1.30B
Cash, Cash Equivalents and Short-Term Investments	254.79M	―	262.02M	373.88M	694.83M	882.77M
Total Debt	35.32M	―	41.20M	50.17M	38.88M	16.34M
Total Liabilities	175.86M	―	179.42M	138.24M	144.30M	129.54M
Stockholders Equity	880.05M	―	892.87M	955.41M	1.23B	1.17B
Cash Flow
Free Cash Flow	-7.58M	―	-5.15M	-73.67M	-57.95M	-5.75M
Operating Cash Flow	29.33M	―	37.73M	-4.47M	33.61M	32.48M
Investing Cash Flow	-118.84M	―	-120.07M	-55.53M	-209.50M	-125.12M
Financing Cash Flow	-14.34M	―	-16.38M	-263.28M	-10.20M	756.56M

Carasent AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 26.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARA, the sentiment is Negative. The current price of 26.2 is below the 20-day moving average (MA) of 27.13, below the 50-day MA of 26.90, and below the 200-day MA of 26.27, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 39.57 is Neutral, neither overbought nor oversold. The STOCH value of 8.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CARA.

Carasent AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CARA	58 Neutral	kr1.89B	-240.37	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Carasent AB Corporate Events

Carasent AB Appoints 2026 Nomination Committee

Carasent AB has announced the appointment of its Nomination Committee for the 2026 Annual General Meeting, consisting of representatives from its three largest shareholders. The committee, chaired by Niclas Lindlöf, will prepare proposals for the meeting, including board member nominations and remuneration details, with the meeting scheduled for April 20, 2026, in Stockholm.